Sunday, May 25, 2014

US FDA approves novel lipoglycopeptide antibiotics dalbavancin Vancomycine class of antibiotic

Novel lipoglycopeptide antibiotics dalbavancin for treating MRSA and Methicilline susceptible skin infections.

Vancomycine is used as last resort drug, an antibiotic in treatment of serious gram positive infection,  methicillin-resistant Staphylococcus aureus, and Streptococcus pyogenes infections, use of Vancomycine is not advisable in treatment of methicillin-susceptible infections, in order to prevent development of resistance to antibiotic vancomycine which is the only last resort drug. Penicilline too cannot be used in individuals with serious allergy to penicillins and they cannot be treated with methicilline.

Inorder to overcome this situation a drug which is as good as vancomycine and can be used to treat methicillin-susceptible strains a novel lipoglycopeptide antibiotics dalbavancin is developed.

Drug Dalvance dalbavancin is a semi synthetic lipoglycopeptide antibiotic which belongs to vancomycine class of antibiotics (lipoglycopeptide antibiotics) it is approved by US FDA on 23-May-2014 for treatment of bacterial skin and skin structure infections (ABSSSI) caused by -susceptible and methicillin-resistant strains of S. aureus and S. pyogenes. It has antibacterial as well as antifungal activity comparable to vancomycine.

Dalvance dalbavancin is first drug to be designated by Us FDA as a Qualified Infectious Disease Product (QIDP) for approval of life saving drug used to treat serious infections it has exhibited similar activity as that of vancomycine in clinical trials.

Drug dalbavancin is required to be adjusted for dose in patients with renal impairment.Liver enzymes are required to be monitored in event of prolonged treatment.

Also see : Vancomycine antibiotic analog work in case bacteria develop activate antibiotic resistance.

No comments: